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ABSTRACT  40 
BACKGROUND: Glucocorticoids can lead to weight gain during cancer treatment, but we know little 41 
about their long-term effects in childhood cancer survivors (CCS).  42 
METHODS: As part of the Swiss Childhood Cancer Survivor Study, we sent a questionnaire to CCS 43 
residing in Switzerland aged <21 years at diagnosis, who survived ≥5 years and were 15-45 years old 44 
at survey. We assessed cumulative doses of glucocorticoids from medical records and study protocols 45 
and calculated BMI from self-reported height and weight at survey. We compared prevalence of 46 
overweight between CCS, their siblings, and the general population (Swiss Health Survey, SHS) and 47 
investigated the association of overweight with treatment-related risk factors using multivariable 48 
logistic regression. 49 
RESULTS: The study included 1936 CCS, 546 siblings, and 9591 SHS participants. Median 50 
(interquartile range) age of the CCS at survey was 24 (20-31) years and median time since diagnosis 51 
was 17 (12-22) years. At survey, 26% of CCS were overweight, a proportion comparable to that 52 
among siblings (24%) and the SHS participants (25%). Prevalence of overweight was 24% in CCS 53 
treated with glucocorticoids only (n=686), 37% in those with cranial radiation therapy (CRT) (n=127), 54 
and 49% in those with both glucocorticoids and CRT (n=101), p<0.001. We found no evidence for a 55 
dose-response relationship between cumulative glucocorticoid doses and overweight and no evidence 56 
that CRT modified the effect of cumulative glucocorticoid dose treatment on overweight.  57 
CONCLUSION: This study suggests that glucocorticoids used for the treatment of childhood cancer 58 
are not associated with long-term risk of overweight.   59 
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INTRODUCTION 60 
The glucocorticoids prednisone and dexamethasone are currently part of the standard treatment of 61 
acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), and Hodgkin lymphoma (HL). 62 
Type of glucocorticoid, dose, and duration of treatment can differ by cancer treatment protocol.1 63 
Cancer treatment with glucocorticoids can lead to weight gain originating in physiological e.g. altered 64 
cortisol concentrations and adipose tissue metabolism and psychological changes that among others 65 
may influence appetite and lower energy expenditure due to physical inactivity.1, 2 An excess of dietary 66 
intake and physical inactivity during treatment could be the base for behavioural changes in the long-67 
term leading to continues weight gain during survivorship. Prednisone and dexamethasone have 68 
similar mechanisms of action, but dexamethasone in the dose range commonly used causes more 69 
adverse effects such as acute metabolic side effects, infections, osteopenia, and behavioral 70 
abnormalities.1, 3 Other treatments for childhood cancer can also affect the development of overweight 71 
and obesity in particular cranial radiation therapy (CRT). CRT impairs the hypothalamic-pituitary axis, 72 
which in turn can lead to growth hormone deficiency and leptin insensitivity.4 ALL treatment protocols 73 
have not routinely prescribed CRT since the 1980s, and overall cumulative CRT doses have 74 
decreased.5 In contrast, cumulative glucocorticoid doses have increased in the US, and prednisone 75 
has been partly replaced by the more potent dexamethasone.6, 7 Many CCS are overweight, especially 76 
in the US, despite decreased doses of CRT.8  77 
 78 
Glucocorticoids might, therefore, be implicated in excessive weight gain during cancer treatment.3, 7 79 
But whether glucocorticoids have a longer-lasting effect on weight is uncertain, and any such effect 80 
may depend on the dose and duration of treatment. Research has yielded contradictory results. One 81 
small (N=169) study of ALL survivors reported a six-fold increased risk of being overweight or obese in 82 
ALL survivors with the highest cumulative doses of glucocorticoids (≥10,000 mg/m2) compared to the 83 
lowest doses (<7500 mg/m2) five years after diagnosis,9 while another US study found no dose-84 
response effects ≥10 years after diagnosis.10 In an US study glucocorticoid treatment was associated 85 
with obesity 25 years after diagnosis in 776 CCS who were treated with CRT, but cumulative dose and 86 
type of glucocorticoid were not assessed.11 Previous studies have mainly focused on acute effects of 87 
glucocorticoids during or shortly after treatment,9, 12-16 have not assessed cumulative glucocorticoid 88 
dose,11, 13 and often have relatively low numbers of participants (<200).9, 12-18 Thus it remains unclear 89 
whether glucocorticoids affect overweight in CCS long after treatment.  90 
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 91 
We analyzed data from the Swiss Childhood Cancer Survivor Study (SCCSS) to investigate whether 92 
1) overweight in long-term CCS (on average 17 years after diagnosis) is associated with the 93 
cumulative glucocorticoid dose received, 2) there is a dose-response relationship between cumulative 94 
glucocorticoid dose and BMI, and 3) the respective effects of prednisone and dexamethasone differ. 95 
We studied the entire group of CCS, and separately the three cancer types treated most frequently 96 
with glucocorticoids (ALL, NHL, and HL). 97 
 98 
METHODS 99 
Sampling 100 
The Swiss Childhood Cancer Survivor Study  101 
The Swiss Childhood Cancer Survivor Study (SCCSS) is a long-term follow-up study of patients 102 
registered in the Swiss Childhood Cancer Registry (SCCR, www.childhoodcancerregistry.ch) who 103 
have been diagnosed since 1976 and survived ≥5 years after cancer diagnosis.19 The SCCR is a 104 
population-based registry that includes all children and adolescents under age 21 in Switzerland who 105 
are diagnosed with leukemia, lymphoma, central nervous system (CNS) tumors, malignant solid 106 
tumors, or Langerhans cell histiocytosis.20, 21 Ethical approval of the SCCR and the SCCSS has been 107 
given by the Ethics Committee of the Canton of Bern to (KEK-BE: 166/2014).  108 
 109 
As part of the SCCSS, we traced addresses of all CCS diagnosed between 1976-2005, who we sent 110 
questionnaires between 2007-2013. A second questionnaire was sent to nonresponders four to six 111 
weeks later. If they again did not respond, we contacted them by phone. Our questionnaire included 112 
core questions from the US and UK CCS studies,22, 23 with added questions about health behaviors 113 
and sociodemographic measures from the Swiss Health Survey (SHS)24 and the Swiss Census.25 114 
Detailed information on our study design has been published previously.19, 26  115 
 116 
Comparison groups 117 
We used two comparison groups in this study: siblings of the CCS and a random sample of the 118 
general Swiss population represented by data from the Swiss Health Survey (SHS). The sibling survey 119 
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was conducted from 2009 to 2012. We asked CCS for consent to contact siblings and for contact 120 
information. We sent siblings the same questionnaire as CCS, omitting questions about cancer history. 121 
Siblings who did not respond received another copy of the questionnaire four to six weeks later, but 122 
were not contacted by phone.19  123 
 124 
The second comparison group consisted of participants in the SHS questionnaire 2012.24 This is a 125 
nationally representative telephone survey repeated every five years. The SHS compiled a randomly 126 
selected sample of Swiss households with telephone landlines and attempted to contact someone in 127 
each household. Sampling was stratified by region and in the selected households the survey was 128 
administered to the consenting household member, age 15 years or older, who first answered the 129 
phone. 130 
 131 
Measurements  132 
Body weight and BMI 133 
Body weight and height at the time of survey were collected from the questionnaires. We instructed all 134 
study participants and control groups to record height without shoes and weight without clothes. We 135 
calculated BMI by dividing weight by height in meters squared (kg/m2). Adult BMI <18.5 kg/m2 was 136 
classified as underweight, ≥18.5 to <25 kg/m2 as normal weight, and ≥25 kg/m2 as overweight 137 
including obesity.27 For adolescents 15-19 years at survey, we standardized BMI into z-scores for age 138 
and gender using the latest available Swiss references.28 BMI z-scores lower than -2 were classified 139 
as underweight, from -2 to 1 as normal weight, and >1 as overweight including obesity.29  140 
 141 
Glucocorticoids 142 
We calculated prednisone and/or dexamethasone doses based on the intended doses in the cancer 143 
treatment protocol and, if applicable, the treatment arm. Glucocorticoid tapering was taken into 144 
account if protocols indicated this. In the event tapering information on duration and dosage was 145 
missing, we assumed that the dosage decreased by 50% of the prior dose in three steps over three 146 
days. The few protocols (3%) that prescribed glucocorticoids by body weight (mg/kg) were converted 147 
into dose per body surface area (mg/m2) by multiplying the dose in mg/kg by a conversion factor of 30, 148 
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which represents an average of the factors for persons weighing 20 and 60 kg.30 Glucocorticoids 149 
administered by intrathecal route and for supportive care or immunosuppression, were not taken into 150 
consideration.1 Treatment protocols that were included came from the Swiss Pediatric Oncology 151 
Group (31%), Pediatric Oncology Group (29%), Berlin/Frankfurt/Muenster study group (24%), German 152 
Society of Pediatric Oncology and Hematology (7%), and others (9%) (Supplementary Table 1). In 67 153 
cases in which the study arm was unknown, survivors were assigned to the protocol arm with the 154 
lowest glucocorticoid dosage. We calculated the total cumulative glucocorticoid dose in equivalent of 155 
prednisone for each patient using the formula cumulative glucocorticoid dose = cumulative prednisone 156 
dose + (cumulative dexamethasone dose x 6.67) in mg/m2.31 The recommended cumulative 157 
glucocorticoid doses dropped over time when all cancer types were combined, and specifically for 158 
each type of cancer with the exception of ALL protocols, in which doses increased (Supplementary 159 
Figure 1). We assessed other clinical and sociodemographic variables as described previously.26  160 
 161 
Statistical analysis 162 
We included all SCCSS survivors and their siblings, and the SHS participants in the general 163 
population, who were aged 15-45 years at time of survey and provided self-reported height and weight 164 
(Supplementary Figure 2). We excluded CCS with hematopoietic stem cell transplantation (HSCT); 165 
this specific group is at substantial risk of underweight due to chronic graft-versus-host disease and 166 
long-term immunosuppression with recurrent infections.32 For better comparison between CCS and 167 
peers, we standardized comparison groups for gender, age at survey, migration background, and 168 
language region as described previously.26 First, we assessed whether overweight at survey was 169 
associated with the cumulative glucocorticoid dose during treatment. We determined these 170 
associations using multivariable logistic regression within all CCS, and within patients with the three 171 
cancer types frequently treated with glucocorticoids. We divided BMI into two categories: overweight 172 
(overweight and obesity) versus non-overweight (underweight and normal) because the group of 173 
obese people was small and the glucocorticoids and CRT risk estimates for the two categories 174 
overweight and obesity had the same direction and comparable magnitude. Cumulative prednisone 175 
and glucocorticoid usage was divided into three categories: lower than the median intake of all CCS, 176 
median to third quartile, and equal to or higher than the third quartile. Cumulative dexamethasone was 177 
divided into two categories: lower than the median intake of all CCS, and equal to or higher than the 178 
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median. We adjusted the models for gender, age at diagnosis, time since diagnosis, and cumulative 179 
CRT and/or glucocorticoid dose. We used interaction terms to test whether age, gender, and the 180 
clinical variables e.g. age at diagnosis, year of diagnosis, time since diagnosis, and CRT modified the 181 
effect of cumulative glucocorticoid dose treatment on overweight since these variables are related to 182 
the total dose. Second, we illustrated the dose-response relationship by comparing the distribution of 183 
BMI by cumulative glucocorticoid dose in steps of 1000 mg/m2 (prednisone and total glucocorticoids) 184 
or 100 mg/m2 (dexamethasone) with boxplots. Because 26% of CCS were 15-19 years at survey, we 185 
used BMI Z-scores for all CCS. We used trend tests to test for an ordered relationship between 186 
cumulative glucocorticoid dose categories and BMI Z-scores. Third, we examined whether effects 187 
differed between dexamethasone and prednisone treatment again using multivariable logistic 188 
regression models. Finally, we performed sensitivity analyses to compare standardized data for 189 
gender, age, migration background, and language region in all comparison groups according to the 190 
distribution in CCS to non-standardized data. For the 67 survivors for whom the study arm was 191 
unknown we performed sensitivity analyses in which they were excluded or were assigned to the 192 
protocol arm with the highest glucocorticoid dose instead of the lowest. We used Stata (version 14, 193 
Stata Corporation, Austin, Texas) for all statistical analyses.  194 
 195 
RESULTS 196 
Response rate and characteristics of the study populations 197 
Among 4116 eligible CCS we traced and contacted 3593 of whom 2527 returned the SCCSS 198 
questionnaire. We excluded 119 participants who did not report height and weight, 355 who were 199 
younger than 15 or older than 45 years, and a further 117 who had received HSCT. We thus included 200 
1936 CCS in this study, of whom 546 had been treated for ALL, 114 NHL, 195 HL, and 1081 for other 201 
types of cancer (Supplementary Figure 2).  202 
 203 
We received consent to contact 1530 siblings, of whom 866 returned the questionnaire; 300 were 204 
outside the age range, and 20 did not report height and weight, thus 546 siblings were finally included 205 
in the analyses. Of 41,008 households surveyed in the general population (SHS), 21,597 replied to the 206 
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survey. In those responding households, 9591 persons who were aged 15-45 years were included in 207 
the analysis. 208 
 209 
Among CCS, median age at diagnosis was 8 (IQR 4–13) years overall, 5 (3–9) years for ALL, 11 (8–210 
14) for NHL, and 14 (12–16) for HL survivors (Table 1). The median time from diagnosis to survey was 211 
17 (IQR 12–22) years for CCS overall, 18 (13–23) for ALL, 17 (12-22) for NHL, and 15 (10-21) for HL 212 
survivors. Most ALL survivors had received glucocorticoids (96% prednisone, and 34% 213 
dexamethasone). NHL and HL were less often treated with glucocorticoids (86% NHL, and 59% HL). 214 
Sociodemographic characteristics were mostly identical between CCS and the comparison groups 215 
after standardization, except that fewer CCS than both siblings and the general population completed 216 
tertiary education (Table 2). CCS engaged in less sports than siblings, but were comparable to the 217 
general population.  218 
 219 
Overweight and glucocorticoid therapy  220 
The prevalence of overweight among all CCS was 26% at survey. This was similar to the overweight 221 
prevalence in the comparison groups after standardization according to CCS: 24% in siblings (p=0.34) 222 
and 25% in the general population (p=0.48) (Table 2, Supplementary Figure 3). When we stratified 223 
CCS by the treatment, we found that the prevalence of overweight was 23% in CCS treated with no 224 
glucocorticoids and no CRT (205 of 889), 24% in those treated with glucocorticoids alone (166 of 686), 225 
37% in CCS treated with ≥20 Gy CRT (47 of 127, p<0.01), and 49% in those treated with both 226 
glucocorticoids and ≥20 Gy CRT (49 of 101, p<0.001) (Figure 1). There was a weak trend (p=0.08), 227 
suggesting an interaction that the effect of CRT tended to be higher in CCS also treated with 228 
glucocorticoids.  229 
 230 
In multivariable logistic regression models we found that overweight was not associated with 231 
cumulative glucocorticoid dose either in CCS overall or in the three cancer types treated frequently 232 
with glucocorticoids (Table 3). But, CCS and ALL survivors treated with ≥20 Gy CRT were more likely 233 
to be overweight. Interaction tests did not suggest that the cumulative effect of glucocorticoids differed 234 
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by gender, age, year of diagnosis, time since diagnosis, chemotherapy, CRT, or history of relapse 235 
(Supplemental Table 2).  236 
 237 
Dose-response relationship between overweight and glucocorticoids  238 
We found no evidence supporting a dose-response relationship between cumulative prednisone, 239 
dexamethasone, or both combined and BMI Z-scores, either when stratifying for CRT (ptrend no 240 
CRT=0.994, ptrend <20Gy=0.510, and ptrend ≥20Gy= 0.174, Figure 2), or when analyzing the entire CCS 241 
group adjusted for cumulative CRT dose (ptrend prednisone=0.085, ptrend dexamethasone=0.176, and ptrend 242 
glucocorticoids =0.583 Supplementary Figure 4). CCS who got high prednisone doses (≥8000 mg/m2) 243 
tended to have higher BMI Z-scores. In ALL survivors we also observed no dose-response relationship 244 
(ptrend prednisone=0.223, ptrend dexamethasone=0.063, and ptrend glucocorticoids =0.512, Supplementary Figure 5). 245 
 246 
Prednisone versus dexamethasone 247 
In unadjusted analyses, CCS who were treated with the highest cumulative dose of prednisone (≥5824 248 
mg/m2) tended to be more overweight than those treated with the lowest dose (<2520 mg/m2). This 249 
was not significant after adjustment for time since diagnosis. We made further adjustments for gender, 250 
age at diagnosis, cumulative cranial radiation therapy, and dexamethasone (Table 3). In contrast, ALL 251 
survivors who were treated with at a higher dexamethasone dose (≥1260 mg/m2) were less likely to be 252 
overweight than those treated with a lower dose (<1260 mg/m2).  253 
 254 
DISCUSSION  255 
At a median 17 years after cancer diagnosis, 26% of CCS in Switzerland were overweight. This 256 
prevalence is comparable to that in siblings and healthy peers in the general population. Prevalence of 257 
overweight was 23% in those CCS treated with glucocorticoids, but higher for CCS treated with cranial 258 
radiation ≥20 Gy (37%), and yet higher among CCS treated with both glucocorticoids and cranial 259 
radiation ≥20 Gy (49%). The effect of CRT on overweight tended to be higher if CCS were also treated 260 
with glucocorticoids, but power for interaction tests was low. There was no evidence for a dose-261 
11 
 
response relationship between the cumulative glucocorticoid dose and being overweight, except for a 262 
possible effect at the highest doses (prednisone ≥8000 mg/m2).  263 
 264 
Overweight and obesity during treatment is frequent in ALL patients who receive high doses of 265 
glucocorticoids,33 but the long-tern impact of glucocorticoids on overweight has not been well studied. 266 
An US study of 784 ALL survivors followed over 26 years found an association of obesity with CRT, 267 
but not cumulative glucocorticoid dose. That finding is similar to ours, but ALL survivors with low 268 
glucocorticoid doses in the US study received high CRT doses. This could have masked an 269 
association between glucocorticoids and obesity.34 A Dutch study of 113 ALL survivors 10 years after 270 
treatment found that higher cumulative prednisone doses led to higher BMI Z-scores at end of 271 
treatment and shortly thereafter, but not in the long-term.18 The cumulative prednisone doses in the 272 
study were much higher than ours; of the 65 survivors who received only prednisone 60 (92%) 273 
survivors had received a cumulative dose of 9800 mg/m2, or more. We also found post hoc evidence 274 
that higher cumulative prednisone doses (≥8000 mg/m2) lead to more overweight, but after 275 
multivariable adjustment this effect disappeared. A dose-response association between cumulative 276 
glucocorticoid dose and BMI was also seen in a longitudinal single-center study in the US of 165 ALL 277 
survivors. BMI was assessed five years after diagnosis and again, cumulative glucocorticoid doses 278 
were higher (around 50% had a cumulative dose of >9000 mg/m2).9 We found in univariable analyses 279 
that survivors who got the highest cumulative prednisone dose (≥5824 mg/m2) were more likely to be 280 
overweight. After adjustment, the association was similar in magnitude and direction, but was no 281 
longer significant. We did not find an association between cumulative dexamethasone and overweight 282 
in CCS. However, follow-up time was longer in CCS treated with prednisone because dexamethasone 283 
was introduced more recently. ALL survivors who got a cumulative dexamethasone dose of ≥1260 284 
mg/m2 were even less likely to be overweight than those who were treated with a lower dosage. The 285 
dose-response relationship between cumulative dexamethasone and BMI Z-scores showed a dent 286 
with higher doses of dexamethasone. Given the wide confidence intervals this finding is most likely 287 
due to chance. The dint could also be a surrogate for more severe disease and more intense 288 
treatment, leading to less weight gain over time. Studies that look at the association between 289 
glucocorticoids and overweight in survivors of tumors other than ALL are limited. In 88 HL survivors in 290 
complete continuous remission for 16 years, no difference in BMI was found between those treated 291 
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with and without prednisone.17 The glucocorticoid dose is lower and chemotherapy duration is shorter 292 
in HL compared to ALL survivors. We saw no association between glucocorticoids and overweight in 293 
either survivor group. 294 
 295 
This study is the largest of its kind to have looked at cumulative glucocorticoid dose and overweight in 296 
CCS long after end of treatment. It also had a specific focus on ALL, NHL, and HL survivors who 297 
usually receive high doses of glucocorticoids. Other strengths include its national coverage and high 298 
response rate, which increase confidence that the results are representative, as does its access to 299 
both socioeconomic factors and detailed treatment data. We also compared CCS with two other 300 
groups from whom contemporaneous data were collected: CCS siblings, and the general population in 301 
Switzerland. Among the study’s limitations was the unavailability of patient dose levels, which 302 
necessitated deriving cumulative glucocorticoid doses from cancer protocol information. This could 303 
have led to either under- or over estimation of the cumulative glucocorticoid dose when the protocol 304 
arm was unknown. But for only 67 survivors was the study arm unknown. Sensitivity analyses where 305 
we excluded those with unknown study arms or were we assigned them to the highest dose instead of 306 
the lowest dose found the same results. Only 239 CCS were treated with dexamethasone because, 307 
though we included CCS diagnosed since 1976, dexamethasone use has increased only recently.7 308 
Height and weight at survey were self-reported; both under- and over-reporting could have occurred. 309 
However, since height and weight were self-reported in all study populations we expected the degree 310 
of nondifferential errors of BMI assessment to be similar across all CCS, the comparison groups, and 311 
across CCS treated with different glucocorticoid doses. Finally, we used BMI as a measure of 312 
overweight. BMI measures neither the ratio of lean to fat mass nor fat distribution. Since 313 
glucocorticoids have a catabolic effect on muscle, CCS could have less lean mass and more fat mass 314 
than the general population with a similar BMI.35 However, BMI is a practical and inexpensive proxy 315 
measure of overweight that is widely used in population-based studies. 316 
 317 
Treatment of childhood cancer increases survivors’ risk of chronic diseases. Overweight can worsen 318 
disease burden, in particular when it involves development of endocrine complications such as type II 319 
diabetes. While our study does not suggest glucocorticoids are associated with long-term overweight, 320 
advice on weight control, a healthy lifestyle, and physical activity should always be part of survivorship 321 
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care, with a special focus on patients who received CRT as well as potentially those who received very 322 
high doses of glucocorticoids.  323 
 324 
Essentially, however, the findings of our study are comforting: treatment with glucocorticoids leads to 325 
overweight at the time of treatment,9, 12-14, 16 but our results suggests that glucocorticoid treatment is 326 
not a reason for concern for long term overweight in CSS. 327 
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TABLE 1. Clinical characteristics of childhood cancer survivors  
 CCS 
(n=1936) 
ALL survivors 
(n=546) 
NHL survivors 
(n=114) 
HL survivors 
(n=195) 
Characteristics n       (%) n       (%) p-valuea n      (%) p-valuea n       (%) p-valuea 
Age at diagnosis, median (IQR) 7.8    (3.7-13.1) 5.1    (3.1-9.1) <0.001 11.1 (7.7-14.0) <0.001 14.2  (11.6-15.9) <0.001 
Time since diagnosis, median (IQR) 16.5  (11.8-22.1) 18.1  (13.3-23.3) <0.001 16.8 (11.6-22.0) 0.918 14.7  (9.5-21.4) <0.001 
Year of diagnosis  
  1976-1988 
  1989-1996  
  1997-2005  
 
667   (34) 
703   (36) 
566   (29) 
 
242   (44) 
187   (34) 
117   (21) 
 
<0.001 
 
41    (36) 
44    (39) 
29    (25) 
 
0.653 
 
50     (26) 
58     (30) 
87     (45) 
 
<0.001 
History of relapse 194   (10) 58     (11) 0.580 8       (7)  0.271 13     (7) 0.100 
Chemotherapy 1494 (77) 546   (100)  <0.001 111  (97)b <0.001 171   (88) <0.001 
Prednisone exposurec 
  Dose, median (IQR), mg/m2 
852   (44) 
2520 (1680-5824) 
524   (96)  
2880 (1680-5824) 
<0.001 84     (74)  
1836 (1836-3880) 
<0.001 116   (59) 
3060 (2340-4824) 
<0.001 
Dexamethasone exposurec 
  Dose, median (IQR), mg/m2 
239   (12) 
1260 (250-1260) 
183   (34)  
1260 (770-1260) 
<0.001 34     (30) 
236   (200-240) 
<0.001 - 
n.a. 
<0.001 
Glucocorticoidsc 
  Dose, median (IQR), mg/m2 
882   (46) 
3470 (1960-8100) 
528   (97)d 
5824 (3360-10084) 
<0.001 98     (86) 
2520 (1836-3516) 
<0.001 116 (59) 
3060 (2340-4824) 
<0.001 
CRT 
  Yes, <20 Gy 
  Yes, ≥20 Gy 
 
133   (7) 
228   (12) 
 
71     (13)  
65     (12) 
 
<0.001 
 
4      (4) 
11    (10) 
 
0.234 
 
17     (9) 
4       (2) 
 
<0.001 
Glucocorticoids and CRT 
  No glucocorticoids and No CRT 
  Glucocorticoids only 
  <20 Gy CRT only 
  ≥20 Gy CRT only  
  Glucocorticoids and <20 Gy CRT  
  Glucocorticoids and ≥20 Gy CRT 
 
889   (46) 
686   (35) 
38     (2) 
127   (7) 
95     (5) 
101   (5) 
 
17     (3)  
393   (72) 
1       (<1) 
- 
70     (13) 
65     (12) 
 
<0.001 
 
16     (14) 
83     (73) 
- 
- 
4       (4) 
11     (10) 
 
<0.001 
 
72   (37) 
102 (52) 
7     (4) 
- 
10   (5) 
4     (2) 
 
<0.001 
ALL, acute lymphoblastic leukemia; CCS, childhood cancer survivors; CRT, cranial radiation therapy; HL, Hodgkin lymphoma; IQR, interquartile range; NHL, non-
Hodgkin lymphoma 
a p-value calculated from two-sample mean comparison test (t test) or chi-square statistics comparing separate diagnostic groups with remaining CCS (2-sided test). 
b n=3 is missing (3%). 
c Protocols with an unknown glucocorticoid dose were not taken into account. Survivors who were treated with unknown dose: 1st protocol: prednisone N=31 
(2%), dexamethasone N=19 (<1%); 2nd protocol: prednisone N=7 (<1%), dexamethasone N=6 (<1%); and 3rd protocol: prednisone N=2 (<1%), 
dexamethasone N=2 (<1%). 
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e Of the 18 survivors who did not receive glucocorticoids during their treatment, N=13 (72%) had no protocol information in their medical records, N=5 (28%) 
got a classification protocol, after which no protocol information was given in their medical record, N=9 (50%) survivors were diagnosed before 1990. 
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TABLE 2. General characteristics of childhood cancer survivors, their 
siblings, and the general population (Swiss Health Survey)  
 CCS 
(n=1936) 
Siblingsa 
(n=725) 
General populationa 
(n=9591) 
Characteristics n       (%)  n     (%std)  p-valueb n       (%std)   p-valueb 
Gender 
  Male 
 
1034 (53)  
 
301 (54) 
 
n.a. 
 
4645 (54) 
 
n.a. 
Age at survey, y  
  15-19 
  20-24 
  25-29 
  30-34 
  35-45 
 
509   (26) 
504   (26) 
388   (20) 
259   (13) 
276   (14) 
 
142 (26) 
162 (24) 
168 (23) 
115 (13) 
138 (14) 
 
n.a. 
 
1518 (33) 
1440 (23) 
1174 (13) 
1424 (11) 
4035 (19) 
 
n.a. 
Parents’ education (highest degree)c 
  Primary  
  Secondary  
  Tertiary  
 
33     (6) 
302   (59) 
174   (34) 
 
6   (4) 
77 (54) 
59 (42) 
 
0.243 
 
n.a. 
 
Personal educationd 
  Primary  
  Secondary  
  Tertiary  
 
108   (8) 
966   (68) 
353   (25) 
 
24   (4) 
359 (62) 
200 (35) 
 
<0.001 
 
691   (8) 
4549 (62) 
2833 (30) 
 
<0.001 
Migration background 453   (23) 132 (23) n.a. 3454 (23) n.a. 
Sportse 1281 (66) 506 (71) 0.041 5598 (64) 0.051 
BMI at survey 
  Underweight 
  Normal 
  Overweight 
  Obese 
 
113   (6) 
1321 (68) 
372   (19) 
130   (7) 
 
19   (2) 
523 (74) 
149 (20) 
34   (4) 
 
<0.001 
 
349   (3) 
6354 (72) 
2285 (24) 
603   (6) 
 
<0.001 
BMI, body mass index; CCS, childhood cancer survivors; n.a., not applicable;  
a Standardized on gender, age at survey, migration background, and language region according to CCS. 
b p-value calculated from chi-square statistics comparing comparison group to CCS (2-sided test). 
c Highest parental education level of participants <20 years at time of survey. 
d Highest personal education level of participants ≥20 years at time of survey.  
e Sports participation was classified as sports if respondents reported engaging in a specific gym or sports activity for at least 
one hour per week. 
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TABLE 3. Crude and adjusted odds ratios for being overweight in childhood cancer survivors treated with different doses of 
cumulative glucocorticoid and cranial radiation therapy 
ALL, acute lymphoblastic leukemia; CCS, childhood cancer survivors; CI, confidence interval; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; OR, odd ratio 
a Adjusted for gender, age at diagnosis, time since diagnosis, cumulative cranial radiation therapy, and glucocorticoid dose (prednisone only, dexamethasone only, or both). 
b Global p-value calculated from the likelihood ratio test. 
 CCS  
(n=1936) 
ALL survivors 
(n=546) 
NHL survivors 
(n=114) 
HL survivors  
(n=195) 
 now/ntotal Crude OR  
(95% CI) 
Adj OR  
(95% CI)a 
now/ntota
l 
Crude OR  
(95% CI) 
Adj OR  
(95% CI)a 
now/ntota
l 
Crude OR 
(95% CI) 
Adj OR  
(95% CI)a 
now/ntota
l 
Crude OR  
(95% CI) 
Adj OR  
(95% CI)a 
Cumulative prednisone (mg/m2) 
  <2520 
  2520-5823 
  ≥5824 
p-valueb 
  375/1489 
54/220 
73/227 
1.00 (ref)  
0.97 (0.70-1.34) 
1.41 (1.04-1.90) 
                 0.081 
1.00 (ref) 
0.87 (0.62-1.22) 
1.24 (0.90-1.70) 
                 0.236 
60/255 
32/111 
54/180 
1.00 (ref)  
1.32 (0.80-2.18) 
1.39 (0.91-2.14) 
                  0.276 
1.00 (ref)  
0.69 (0.37-1.28) 
0.78 (0.45-1.34) 
                  0.481 
23/74 
6/25 
5/15 
1.00 (ref)  
0.70 (0.25-1.98) 
1.11 (0.34-3.61) 
                  0.754 
1.00 (ref)  
0.45 (0.13-1.56) 
0.51 (0.14-1.87) 
                  0.351 
34/119 
9/49 
10/27 
1.00 (ref)  
0.56 (0.25-1.28) 
1.47 (0.61-3.53) 
                  0.179 
1.00 (ref) 
0.61 (0.25-1.48) 
1.02 (0.37-2.84) 
                     0.506 
Cumulative dexamethasone (mg/m2) 
  <1260 
  ≥1260 
p-valueb 
478/1813 
24/123 
 
1.00 (ref)  
0.68 (0.43-1.07) 
                 0.084 
1.00 (ref)  
0.78 (0.49-1.24) 
                 0.286 
123/424 
23/122 
1.00 (ref) 
0.57 (0.34-0.94) 
                  0.022 
1.00 (ref) 
0.54 (0.31-0.93) 
                  0.025 
34/114 
   - 
 
1.00 (ref) 
- 
                   
1.00 (ref)  
- 
                      
53/195 
- 
1.00 (ref) 
- 
                   
1.00 (ref)  
- 
                      
Cumulative glucocorticoids (mg/m2) 
  <3470 
  3470-8099 
  ≥8100 
p-valueb 
381/1495 
60/219 
61/222 
1.00 (ref)  
1.10 (0.80-1.52) 
1.11 (0.81-1.52) 
                 0.715 
1.00 (ref) 
1.04 (0.75-1.45) 
1.07 (0.78-1.49) 
                 0.900 
60/214 
44/152 
42/180 
1.00 (ref)  
1.05 (0.66-1.66) 
0.78 (0.49-1.23) 
                   0.438 
1.00 (ref)  
1.15 (0.70-1.87) 
0.63 (0.39-1.03) 
                 0.073 
25/89 
5/15 
4/10 
 
1.00 (ref)  
1.28 (0.40-4.12) 
1.71 (0.44-6.56) 
                  0.710 
1.00 (ref)  
1.28 (0.33-5.04) 
1.01 (0.24-4.24) 
                  0.940 
38/138 
5/30 
10/27 
 
1.00 (ref)  
0.53 (0.19-1.47) 
1.55 (0.65-3.68) 
                  0.212 
1.00 (ref)  
0.44 (0.15-1.34) 
0.96 (0.34-2.68) 
                     0.300 
CRT 
  No CRT 
  <20 Gy 
  ≥20 Gy 
p-valueb 
371/1575 
35/133 
96/228 
1.00 (ref) 
1.16 (0.77-1.73) 
2.36 (1.77-3.15) 
               <0.001 
1.00 (ref) 
1.16 (0.76-1.77) 
2.28 (1.70-3.06) 
               <0.001 
97/410 
11/71 
38/65 
1.00 (ref) 
0.59 (0.30-1.17) 
4.54 (2.64-7.82) 
                <0.001 
1.00 (ref) 
0.63 (0.31-1.28) 
4.40 (2.45-7.89) 
                <0.001 
29/99 
1/4 
4/11 
1.00 (ref) 
- 
1.38 (0.37-5.07) 
                  0.871 
1.00 (ref) 
- 
0.84 (0.20-3.46) 
                  0.963 
46/174 
7/17 
-/4 
1.00 (ref) 
1.95 (0.70-5.42) 
- 
                 0.202 
1.00 (ref) 
1.93 (0.65-5.74) 
- 
                     0.237 
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FIGURE 1. Prevalence of overweight in long-term childhood cancer survivors, by 
treatment with glucocorticoids and ≥20 Gray cranial radiation. 
CI, confidence interval; CRT, cranial radiation therapy; Gy, gray. 
Comparison groups were standardized on gender, age at survey, migration background, and language region 
according to CCS. 
All p-values were calculated from chi-square statistics comparing CCS who got no glucocorticoids and no CRT to 
other CCS and comparison groups. 
The dotted line reflects the overweight prevalence of the general population.  
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FIGURE 2. Box-plot of the dose-response relationship between BMI Z-score and 
cumulative glucocorticoid dose stratified by cranial radiation therapy in 
childhood cancer survivors (N=1936) 
BMI, body mass index; CRT, cranial radiation therapy; Gy, gray 
p-values for trend for no CRT 0.658, <20Gy CRT 0.937, and ≥20Gy CRT 0.309 
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SUPPORTING INFORMATION 
 
Supplementary TABLE 1. Protocols of clinical trials included 
Protocol CCS, n (%)  Dexamethasone Prednisonea 
BFM  234 (24%)   
  ALL-BFM 83 1 X X 
  ALL-BFM 86 2 X X 
  ALL-BFM 90 56 X X 
  ALL-BFM 95 64 X X 
  ALL-BFM 99 MRD Pilot 4 X X 
  ALL-BFM 2000 23 X X 
  ALL/NHL-BFM 86 2 X X 
  ALL-REZ-BFM 87 1 X X 
  ALL-REZ-BFM 90 8 X X 
  ALL-REZ-BFM P95/96 8 X X 
  ALL-REZ-BFM 2002 2 X X 
  AML-BFM 87 1  X 
  AML-BFM 93 7  X 
  AML-BFM 98 4  X 
  B-NHL-BFM 04 3 X  
  NHL-BFM 83 3 X X 
  NHL-BFM 90 18 X X 
  NHL-BFM 95 27 X X 
GPOH 64 (7%)   
  ALCL99 (GPOH) 1 X  
  GPOH HD 95 47  X 
  GPOH HD 2002 16  X 
POG 279 (29%)   
  POG-7376 2  X 
  POG-7837 3  X 
  POG-7909 4  X 
  POG-8036 27  X 
  POG-8101 5 X X 
  POG-8304 5  X 
  POG-8314 4  X 
  POG-8426 1  X 
  POG-8602 34  X 
  POG-8616 6  X 
  POG 8618 1  X 
  POG-8691 2  X 
  POG-8704 18  X 
  POG-8710 1  X 
  POG-8719 11  X 
  POG-9005 27  X 
  POG-9006 12  X 
  POG-9061 1 X  
  POG-9201 11  X 
  POG-9219 14  X 
  POG-9310 1  X 
  POG-9315 5  X 
  POG-9398 2  X 
  POG-9404 4  X 
  POG-9405 6  X 
  POG-9406 7  X 
  POG-9411 3 X X 
  POG-9412 4 X  
  POG-9425 2  X 
  POG-9605 16  X 
  POG 9900 12 X X 
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CCS could have received several protocols based on the cancer type, relapse etc. 
ALL, acute lymphoblastic leukemia; ALCL, anaplastic large cell; AML, acute myelogenous leukemia lymphoma; 
BFM, Berlin/Frankfurt/Muenster study group; CALGB, Cancer and Leukemia Group B; CCG, Children’s Cancer 
Group; R-CHOP, rituximab cyclophosphamide hydroxyl-doxorubicin vincristine prednisone; COG, Children’s 
Oncology Group; DAL, German-Austrian multicentre trial; EORTC, European Organisation for Research and 
Treatment of Cancer; EURO, European; GPOH, German Society of Pediatric Oncology and Hematology; HD, 
high dose / Hodgkin’s disease; HR, high risk; LB, lymphoblastic; LCH, Langerhans cell histiocytosis; LMB, B-cell 
non-Hodgkin’s lymphoma and B-ALL; LR, low risk; MRD, minimal residual disease; NHL, non-Hodgkin lymphoma;  
POG, Pediatric Oncology Group; REZ, relapse; SAKK, Swiss Group for Clinical Cancer Research; SIOP, 
International Society of Pediatric Oncology; SPOG, Swiss Pediatric Oncology Group 
a Intrathecal prednisone is not taken into account. 
  
  POG-9904 2 X X 
  POG-9905 7 X X 
  POG-9906 10 X X 
  POG-9917 7 X  
  POG-A5971 2 X X 
SPOG 299 (31%)   
  SPOG ALL 79/84 129  X 
  SPOG ALL LR 76 35  X 
  SPOG ALL HR 76 5  X 
  SPOG ALL HR 79 11  X 
  SPOG ALL REZ LR 77 1  X 
  SPOG ALL REZ HR 77 2  X 
  SPOG NHL (1977) 32  X 
  SPOG H77 26  X 
  SPOG H87 13  X 
  SPOG Hodgkin 1985 10  X 
  SPOG HT(Hirntumor) A76 7  X 
  SPOG HX 28  X 
Other 91 (9%)   
  CALGB 7111 9 X X 
  CALGB 7411 12  X 
  CALGB 7611 16  X 
  CALGB 7721 4  X 
  CCG-2961 1 X  
  COG-AALL0433 2 X X 
  DAL HD 90 4  X 
  DAL HX 90 6  X 
  EORTC 58881 1 X X 
  EURO LB 02 1 X X 
  HD 5 1  X 
  HD 9 1  X 
  LALA 94 1 X X 
  LCH II 17  X 
  LCH III 5  X 
  LMB 84 3  X 
  LMB 89 2  X 
  R-CHOP 1  X 
  SAKK NHL 1  X 
  SIOP HD IV 87 3  X 
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Supplementary TABLE 2. P-values for interaction of glucocorticoid use in 
childhood cancer survivors with sociodemographic and clinical characteristics 
(retrieved from multivariable logistic regressionsa) 
ALL, acute lymphoblastic leukemia; CCS, childhood cancer survivors; HL, Hodgkin lymphoma; NHL, non-Hodgkin 
lymphoma 
a adjusted for gender, age at diagnosis, and time since diagnosis. 
b p-value for interaction was calculated with the likelihood ratio test.  
  
 p-values for interactionsb 
 CCS  
(n=1936) 
ALL 
(n=546) 
NHL 
(n=114) 
HL 
(n=195) 
Sociodemographic     
Gender 0.869 0.283 0.381 0.084 
Age at survey 0.943 0.207 0.466 0.834 
Clinical      
Age at diagnosis, years 0.633 0.800 0.670 0.756 
Year of diagnosis 0.462 0.433 0.700 0.293 
Time since diagnosis, years 0.343 0.502 0.5627 0.580 
Chemotherapy (No, Yes) 0.818 n.a. 0.707 0.434 
Cranial radiation therapy (No, Yes) 0.261 n.a. n.a. 0.422 
History of relapse (No, Yes) 0.138 n.a. n.a. n.a. 
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Supplementary FIGURE 1. Time trends in exposure to glucocorticoids (cumulative dose) 
during treatment in CCS, ALL, NHL, and HL survivors  
ALL, acute lymphoblastic leukemia; CCS, childhood cancer survivors; HL, Hodgkin lymphoma; NHL, non-Hodgkin 
lymphoma 
p-values for testing trend of cumulative glucocorticoid dose across year of diagnosis by childhood cancer type.  
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Supplementary FIGURE 2. Response rates and study populations in the Swiss 
Childhood Cancer Survivor Study 
ALL, acute lymphoblastic leukemia; AML; acute myeloid leukemia; CCS, childhood cancer survivors; CNS, central 
nervous system; HL, Hodgkin lymphoma; HSCT, hematopoietic stem cell transplantation; NHL, non-Hodgkin 
lymphoma; SCCSS, Swiss Childhood Cancer Survivor Study 
 
  
4116 survivors eligible for the SCCSS 
513 no valid address available 
10 had died 
 
3593 (100%) traced and sent questionnaires 
850 (24%) did not respond 
216 (6%) refused 
2527 (70%) returned questionnaire 
119 (3%) had missing data on self-reported 
height and weight at survey 
1936 (54%) available for analyses 
546 (15%) 
ALL survivors 
114 NHL (3%) 
survivors 
355 (10%) were >45 or <15 years old at survey 
1081 (30%) other CCS: 
• 52 Other leukemias, e.g. AML 
• 69 Other lymphomas, e.g. Burkitt 
• 282 CNS neoplasm 
• 76 Neuroblastoma 
• 49 Retinoblastoma 
• 114 Renal tumor 
• 13 Hepatic tumor 
• 88 Malignant bone tumor 
• 114 Soft tissue sarcoma 
• 94 Germ cell tumor 
• 52 Other tumor 
• 78 Langerhans cell histiocytosis 
 
 
117 (3%) had HSCT 
195 HL (5%) 
survivors 
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Supplementary FIGURE 3. Prevalence of overweight in childhood cancer survivors, 
their siblings, and the general population 
ALL, acute lymphoblastic leukemia; CCS, childhood cancer survivors; CI, confidence interval; HL, Hodgkin 
lymphoma; NHL, non-Hodgkin lymphoma  
Comparison groups were standardized on gender, age at survey, migration background, and language region 
according to CCS. 
The dotted line reflects the overweight prevalence in the general population. 
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Supplementary FIGURE 4. Dose-response relationship between cumulative A. 
Prednisone, B. Dexamethasone, C. Glucocorticoids combined (prednisone and 
dexamethasone) and BMI Z-score in childhood cancer survivors (N=1936), adjusted for 
cumulative dose of cranial radiation therapy 
BMI, body mass index; CI, confidence interval; No, number 
p-values for testing trend of BMI Z-score across cumulative glucocorticoid dose.  
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Supplementary FIGURE 5. Dose-response relationship between cumulative A. Prednisone, B. 
Dexamethasone, C. Glucocorticoids combined (prednisone and dexamethasone) and BMI Z-
score in ALL survivors (N=546), adjusted for cumulative dose of cranial radiation therapy  
ALL, acute lymphoblastic leukemia; BMI, body mass index; CI, confidence interval; No, number 
p-values for testing trend of BMI Z-score across cumulative glucocorticoid dose.  
 
